Physician profile
Max K Dweck
NPI 1235177882
$12,841.54
in general payments reported to CMS, 2019-2025
33 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $1,293 · 2021: $1,353 · 2022: $2,018 · 2023: $2,155 · 2024: $2,381 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,761.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,492.54 | 2019-2025 | Jardiance |
| Amgen INC. | $1,367.41 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,134.83 | 2019-2025 | |
| Novo Nordisk INC | $1,058.41 | 2021-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $978.30 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $926.60 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $715.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $675.48 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Pfizer INC. | $656.01 | 2019-2025 | |
| Amarin Pharma, INC. | $569.54 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $538.25 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $480.51 | 2019-2024 | Livalo |
| Heartflow, INC. | $370.63 | 2022-2025 | Ffrct |
| Lilly USA, LLC | $324.06 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Esperion Therapeutics, INC. | $313.24 | 2021-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $176.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $173.38 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $159.64 | 2023-2024 | Inpefa |
| Philips North America LLC | $150.79 | 2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.48 | 2022-2023 | Lifevest |
| Agepha Pharma Fz LLC | $89.43 | 2024-2025 | Lodoco |
| Medicure Pharma INC. | $78.48 | 2021-2025 | Zypitamag |
| Kiniksa Pharmaceuticals International, Plc | $62.81 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $48.99 | 2021-2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $45.43 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.31 | 2019 | |
| Angiodynamics, INC. | $23.15 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.15 | 2019 | |
| Cmp Pharma, INC. | $20.26 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.45 | 2021 | |
| Baxter Healthcare | $18.35 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $17.10 | 2022 | |
| Allergan, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Dweck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.